Quick Answer
AXIM BIOTECHNOLOGIES, INC. reported Operating Income of -$2.75 million for fiscal year 2023.
AXIM BIOTECHNOLOGIES, INC. Operating Income — Annual History
| Fiscal Year | Operating Income | YoY Change |
|---|---|---|
| 2023 | -$2.75M | +40.9% |
| 2022 | -$4.65M | +66.7% |
| 2021 | -$13.97M | -177.5% |
| 2018 | -$5.04M | -59.9% |
| 2017 | -$3.15M | +16.2% |
| 2016 | -$3.76M | — |
Quarterly Operating Income
| Quarter Ending | Operating Income | YoY | QoQ |
|---|---|---|---|
| June 30, 2024 | -$569.4K | +18.4% | -40.8% |
| March 31, 2024 | -$404.4K | +43.1% | +31.3% |
| September 30, 2023 | -$588.5K | +55.3% | +15.6% |
| June 30, 2023 | -$697.7K | +34.2% | +1.8% |
| March 31, 2023 | -$710.6K | +37.3% | +46.1% |
| September 30, 2022 | -$1.32M | +59.8% | -24.3% |
| June 30, 2022 | -$1.06M | +51.4% | +6.4% |
| March 31, 2022 | -$1.13M | -30.5% | +65.4% |
- AXIM BIOTECHNOLOGIES, INC. showed an increase of +40.9% in Operating Income compared to the prior fiscal year.
- Over the 2016–2023 period, AXIM BIOTECHNOLOGIES, INC.’s operating income has grown by 26.8% (from -$3.76 million to -$2.75 million).
- The most recent figure is from AXIM BIOTECHNOLOGIES, INC.’s fiscal year 2023 report (Form 10-K), filed with the SEC on April 16, 2024.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: